K C Lakshmaiah
Overview
Explore the profile of K C Lakshmaiah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
456
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patel A, Bhatt N, Prakash S, Biswas G, Nagarkar R, Roy B, et al.
Cancer Chemother Pharmacol
. 2023 Apr;
91(6):457-468.
PMID: 37093266
Purpose: Very few studies have demonstrated the rituximab biosimilarity in terms of efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity in patients with diffuse large B-cell lymphoma (DLBCL) in India. Therefore, we...
2.
Namratha Udupa M, Govind Babu K, Suresh Babu M, Lakshmaiah K, Lokanatha D, Jacob A, et al.
J Cancer Res Ther
. 2020 May;
16(1):18-22.
PMID: 32362604
Introduction And Aims: Acute myeloid leukemia (AML) in adults has poor prognosis. The epidemiologic profile of patients varies greatly in different geographic locations and so do the cytogenetic abnormalities and...
3.
Rudresha A, Chaudhuri T, Lakshmaiah K, Babu G, Lokesh K, Rajeev L
J Cancer Res Ther
. 2020 May;
16(1):13-17.
PMID: 32362603
Objective: Primary central nervous system lymphoma (PCNSL) is a rare form of aggressive extranodal non-Hodgkin lymphoma. This study attempts to delineate the clinicopathological and radiological profile of PCNSL cases at...
4.
Sinha M, Sundar K, Premalata C, Asati V, Murali A, Bajpai A, et al.
Sci Rep
. 2019 Oct;
9(1):14516.
PMID: 31601912
Non Hodgkin lymphoma, predominantly Diffuse Large B-cell Lymphoma (DLBCL) has been reported to have a significant association with Hepatitis B virus (HBV). We investigated the presence of different gene segments...
5.
Govind Babu K, Chaudhuri T, Lakshmaiah K, Dasappa L, Abraham Jacob L, Suresh Babu M, et al.
South Asian J Cancer
. 2019 May;
8(2):85-87.
PMID: 31069184
Background: Epirubicin, cisplatin, and 5-FU (ECF) is one of the most commonly used first-line chemotherapy regimens in metastatic gastric cancer. However, due to protracted infusion schedule, need for special infusion...
6.
Babu G, Asati V, Lakshmaiah K, Lokanatha D, Abraham Jacob L, Babu S, et al.
Indian J Cancer
. 2019 Apr;
56(1):70-73.
PMID: 30950449
Background: Synchronous occurrence of two malignant tumors is a rare event. With increasing use of sophisticated imaging modalities for staging, synchronous multiple tumors are more commonly detected now. Assuming the...
7.
Rudresh A, Asati V, Lakshmaiah K, Lokanatha D, Babu S, Rajeev L, et al.
J Cancer Res Ther
. 2019 Mar;
15(Supplement):S56-S59.
PMID: 30900622
Context: Renal function assessment is of paramount importance before using the platinum agents especially cisplatin. Glomerular filtration rate (GFR) estimation by diethyl-triamine-penta-acetic acid (DTPA) scan (measured GFR [mGFR]) is considered...
8.
Suresh B, Asati V, Lakshmaiah K, Babu G, Lokanatha D, Abraham Jacob L, et al.
South Asian J Cancer
. 2019 Feb;
8(1):57-59.
PMID: 30766857
Background: Gastrointestinal tract (GIT) is the most common extranodal site for non-Hodgkin's lymphoma (NHL) and constitutes about 10%-15% of all NHL. This was a prospective study to evaluate the epidemiological,...
9.
Lakshmaiah K, Chaudhuri T, Babu G, Dasappa L, Abraham Jacob L, Suresh Babu M, et al.
Indian J Cancer
. 2019 Jan;
55(3):288-291.
PMID: 30693896
Background: Thymic epithelial tumors (TET) are the most common tumors of the anterior mediastinum. Patients with advanced/metastatic disease are usually treated with palliative chemotherapy (CT). Unfortunately, even though various palliative...
10.
Lokesh K, Chaudhuri T, Lakshmaiah K, Govind Babu K, Lokanatha D, Jacob L, et al.
Indian J Cancer
. 2019 Jan;
55(3):257-260.
PMID: 30693890
Background: Recently published prospective clinical trials and two meta-analyses have shown that addition of induction chemotherapy (IC) to concurrent chemoradiation (CRT) could potentially improve outcomes in comparison to CRT alone,...